ClinicalTrials.gg
CompletedNCT04159415Updated Jun 15, 2026Results posted

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

A Phase 2 interventional study of Placebo and Low-Dose REGN4461 in Generalized Lipodystrophy, sponsored by Regeneron Pharmaceuticals. Completed at 8 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL).

The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 3 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.

02

Conditions studied

  • Generalized Lipodystrophy
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of congenital or acquired generalized lipodystrophy (GLD), as defined in the protocol
  • Presence of one or both of the following metabolic abnormalities at screening:

    1. ≥ 7% OR
    2. Fasting TG ≥250 mg/dL
  • Generally stable diet (based on patient's recall) and medication regimen (that optimizes treatment for their metabolic disease) for at least 3 months prior to the screening visit

Key Exclusion Criteria:

  • Treatment with metreleptin within 1 month of the screening visit
  • Treatment with over-the-counter or prescription medications for weight loss within 3 months prior to the screening visit
  • Treatment with oral >7.5 mg prednisone equivalents per day within 3 months prior to screening visit or plans to begin treatment with oral glucocorticoids >7.5 mg prednisone equivalents per day during the study period
  • History of (HIV) or HIV seropositivity at screening visit
  • Uncontrolled infection with or infection, or known active tuberculosis at screening
  • Participation in any clinical research study evaluating an product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit.
  • Pregnant or breast-feeding women

NOTE: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: Placebo · Drug: Low-Dose REGN4461 · Drug: High-dose REGN4461

  • Experimental
    Treatment B

    Drug: Placebo · Drug: Low-Dose REGN4461 · Drug: High-dose REGN4461

Interventions

  • DrugPlacebo

    Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).

  • IV infusion loading dose or SC injection QW.

    Also known as: mibavademab

  • IV infusion loading dose or SC injection QW.

    Also known as: mibavademab

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8

    Absolute change from baseline in HbA1c for subgroup of participants with baseline HbA1c ≥7% reported

    Time frame: Baseline, Week 8

  2. Absolute Change From Baseline in Fasting Glucose at Week 8

    Absolute change from baseline in fasting glucose for subgroup of participants with baseline HbA1c ≥7% reported

    Time frame: Baseline, Week 8

  3. Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8

    Absolute change from baseline in WMG for subgroup of participants with baseline HbA1c ≥7% reported

    Time frame: Baseline, Week 8

  4. Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8

    Percent change from baseline in participants with elevated baseline fasting TG (fasting TG ≥250 mg/dL) reported

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Absolute Change From Baseline in HbA1c and Fasting TG Composite Endpoint at Week 8

    The composite score is calculated for each individual participant using baseline and Week 8 measurements of HbA1c and fasting TG. For each participant, a Z-score is calculated separately for HbA1c and fasting TG, rescaling the change from baseline based on the standard deviation of the baseline value for all participants, as a way of standardizing the change value. The composite score uses one or both of the calculated Z-scores depending on which parameters were abnormal at baseline. If both, then the participant's composite is the average of the two parameter Z-scores. At the participant level, a Z-score of zero for either parameter indicates no change in that metabolic parameter, but a composite Z-score of zero can also reflect offsetting changes in metabolic parameters. A negative Z-score would be interpreted as an overall improvement in metabolic function, but a negative Z-score can also result from a decrease in one parameter not being canceled by an increase in the other.

    Time frame: Baseline, Week 8

  2. Absolute Change From Baseline in Fasting Glucose

    Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52

  3. Absolute Change From Baseline in Fasting Glucose for Participants With Baseline HbA1c ≥7%

    Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52

  4. Percent Change From Baseline in Fasting TG

    Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52

  5. Percent Change From Baseline in Fasting TG for Participants With Baseline Fasting TG ≥250 mg/dL

    Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52

  6. Absolute Change From Baseline in HbA1c

    Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 12, 24, 52

  7. Absolute Change From Baseline in HbA1c for Participants With Baseline HbA1c ≥7%

    Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 12, 24, 52

  8. Absolute Change From Baseline in Weighted Mean Glucose (WMG)

    Time frame: Baseline, Weeks 16 and 24

  9. Absolute Change From Baseline in WMG for Participants With Baseline Fasting HbA1c ≥7%

    Time frame: Baseline, Weeks 16 and 24

  10. Change From Baseline in Glucose Area Under the Concentration-time Curve (AUC0-4) During a Mixed Meal Tolerance Test (MMTT)

    Time frame: Baseline, Weeks 8, 16, 24

  11. Change From Baseline in Glucose AUC0-4 During a MMTT for Participants With Baseline HbA1c ≥7%

    Time frame: Baseline, Weeks 8, 16, 24

  12. Change From Baseline in Glucose Infusion Rate Per Kilogram (kg) Body Mass During Hyperinsulinemia-euglycemic Clamp

    Time frame: Baseline, Weeks 8 and 52

  13. Change From Baseline in Glucose Infusion Rate Per kg Body Mass During Hyperinsulinemia-euglycemic Clamp for Participants With Baseline HbA1c ≥7%

    Time frame: Baseline, Weeks 8 and 52

  14. Change From Baseline in Glucose Clearance Rate (kITT) During Insulin-tolerance Test (ITT)

    Time frame: Baseline, Weeks 8 and 52

  15. Change From Baseline in Glucose kITT During ITT for Participants With Baseline HbA1c ≥7%

    Time frame: Baseline, Weeks 8 and 52

  16. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    Time frame: From first dose of DBTP study treatment through last dose of OLTP 5 study treatment plus 16 weeks (approximately 120 weeks)

  17. Concentrations of Total REGN4461 in Serum Over Time

    Time frame: Weeks 0 (post-dose), 8, 16 (post-dose), 36, 52; OLTP 5 Weeks 4, 12, 24, 52

  18. Number of Participants With Anti-drug Antibodies (ADA) to REGN4461

    Time frame: Approximately Week 128

07

Results

Posted Feb 25, 2025

Participant flow

Double-blind Treatment Period (DBTP) 1
Participant flow — Double-blind Treatment Period (DBTP) 1
MilestoneTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QWTreatment Sequence A, DBTP 2: Low-dose REGN4461 SC QWTreatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QWTreatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 5: High-doseTreatment Sequence B, OLTP 5: High-dose
Started8800000000
Completed8800000000
Not completed0000000000
Double-blind Treatment Period (DBTP) 2
Participant flow — Double-blind Treatment Period (DBTP) 2
MilestoneTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QWTreatment Sequence A, DBTP 2: Low-dose REGN4461 SC QWTreatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QWTreatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 5: High-doseTreatment Sequence B, OLTP 5: High-dose
Started0088000000
Completed0088000000
Not completed0000000000
Double-blind Treatment Period (DBTP) 3
Participant flow — Double-blind Treatment Period (DBTP) 3
MilestoneTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QWTreatment Sequence A, DBTP 2: Low-dose REGN4461 SC QWTreatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QWTreatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 5: High-doseTreatment Sequence B, OLTP 5: High-dose
Started0000880000
Completed0000880000
Not completed0000000000
Open-Label Treatment Period (OLTP) 4
Participant flow — Open-Label Treatment Period (OLTP) 4
MilestoneTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QWTreatment Sequence A, DBTP 2: Low-dose REGN4461 SC QWTreatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QWTreatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 5: High-doseTreatment Sequence B, OLTP 5: High-dose
Started0000008800
Completed oltp 40000008800
Entered oltp 4 extension0000006600
Completed0000006400
Not completed0000002400
Withdrew: Completed wk 52; did not enter oltp 4 extension0000002200
Withdrew: Lost to follow-up during oltp 4 extension0000000100
Withdrew: Completed wk 52; discontinued during oltp4 ext. pi/participant decision0000000100
Open-Label Treatment Period (OLTP) 5
Participant flow — Open-Label Treatment Period (OLTP) 5
MilestoneTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QWTreatment Sequence A, DBTP 2: Low-dose REGN4461 SC QWTreatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QWTreatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QWTreatment Sequence A, OLTP 5: High-doseTreatment Sequence B, OLTP 5: High-dose
Started0000000064
Completed0000000063
Not completed0000000001
Withdrew: Withdrawal by subject0000000001

Outcome measures

SecondaryAbsolute Change From Baseline in HbA1c and Fasting TG Composite Endpoint at Week 8

The composite score is calculated for each individual participant using baseline and Week 8 measurements of HbA1c and fasting TG. For each participant, a Z-score is calculated separately for HbA1c and fasting TG, rescaling the change from baseline based on the standard deviation of the baseline value for all participants, as a way of standardizing the change value. The composite score uses one or both of the calculated Z-scores depending on which parameters were abnormal at baseline. If both, then the participant's composite is the average of the two parameter Z-scores. At the participant level, a Z-score of zero for either parameter indicates no change in that metabolic parameter, but a composite Z-score of zero can also reflect offsetting changes in metabolic parameters. A negative Z-score would be interpreted as an overall improvement in metabolic function, but a negative Z-score can also result from a decrease in one parameter not being canceled by an increase in the other.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · Z-score
Absolute Change From Baseline in HbA1c and Fasting TG Composite Endpoint at Week 8
Z-scoreTreatment Sequence A: DBTP 1:Treatment Sequence B: DBTP 1
Absolute Change From Baseline in HbA1c and Fasting TG Composite Endpoint at Week 80.0 ± 0.20.1 ± 0.3
SecondaryAbsolute Change From Baseline in Fasting Glucose
Time frame:
Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Fasting Glucose
mg/dLTreatment Sequence ATreatment Sequence B
Week 16-29.4 ± 59.80-22.0 ± 47.85
Week 24-68.8 ± 58.74-21.1 ± 82.85
Week 36-47.6 ± 71.0412.5 ± 119.63
Week 52-55.1 ± 77.976.9 ± 68.64
OLTP 5 Week 4-91.8 ± 61.29-39.8 ± 45.36
OLTP 5 Week 12-82.9 ± 63.16-119.9 ± 64.64
OLTP 5 Week 24-100.5 ± 55.15-40.7 ± 110.20
OLTP 5 Week 52-91.0 ± 84.38-111.2 ± 125.57
SecondaryAbsolute Change From Baseline in Fasting Glucose for Participants With Baseline HbA1c ≥7%
Time frame:
Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Fasting Glucose for Participants With Baseline HbA1c ≥7%
mg/dLTreatment Sequence ATreatment Sequence B
Week 16-29.4 ± 59.80-26.3 ± 50.89
Week 24-68.8 ± 58.74-24.5 ± 90.23
Week 36-47.6 ± 71.0413.1 ± 129.20
Week 52-55.1 ± 77.978.2 ± 75.10
OLTP 5 Week 4-91.8 ± 61.29-39.8 ± 45.36
OLTP 5 Week 12-82.9 ± 63.16-119.9 ± 64.64
OLTP 5 Week 24-100.5 ± 55.15-40.7 ± 110.20
OLTP 5 Week 52-91.0 ± 84.38-111.2 ± 125.57
SecondaryPercent Change From Baseline in Fasting TG
Time frame:
Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Fasting TG
Percentage of changeTreatment Sequence ATreatment Sequence B
Week 16-22.5 ± 48.21-50.2 ± 39.99
Week 24-55.1 ± 30.60-45.7 ± 44.61
Week 36-40.2 ± 39.19-43.9 ± 51.07
Week 52-9.7 ± 74.05-60.3 ± 20.38
OLTP 5 Week 4-71.5 ± 18.79-58.2 ± 21.60
OLTP 5 Week 12-56.0 ± 38.07-80.0 ± 17.52
OLTP 5 Week 24-64.4 ± 29.59-67.4 ± 22.32
OLTP 5 Week 52-77.4 ± 13.37-85.8 ± 11.89
SecondaryPercent Change From Baseline in Fasting TG for Participants With Baseline Fasting TG ≥250 mg/dL
Time frame:
Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Fasting TG for Participants With Baseline Fasting TG ≥250 mg/dL
Percentage of changeTreatment Sequence ATreatment Sequence B
Week 16-39.4 ± 36.26-45.4 ± 47.97
Week 24-62.8 ± 30.80-42.4 ± 53.75
Week 36-48.6 ± 41.67-44.0 ± 60.31
Week 520.7 ± 85.36-63.4 ± 22.22
OLTP 5 Week 4-72.2 ± 20.92-58.2 ± 21.60
OLTP 5 Week 12-54.9 ± 42.46-80.0 ± 17.52
OLTP 5 Weeks 24-64.0 ± 33.06-67.4 ± 22.32
OLTP 5 Week 52-77.4 ± 13.37-85.8 ± 11.89
SecondaryAbsolute Change From Baseline in HbA1c
Time frame:
Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 12, 24, 52
Reported as:
Mean · Percentage of HbA1c
Absolute Change From Baseline in HbA1c
Percentage of HbA1cTreatment Sequence ATreatment Sequence B
Week 16-0.60 ± 2.200-0.50 ± 1.664
Week 24-2.34 ± 1.897-0.85 ± 1.998
Week 36-2.56 ± 1.985-0.83 ± 2.147
Week 52-2.69 ± 2.120-1.59 ± 2.338
OLTP 5 Week 12-3.57 ± 1.957-1.53 ± 2.472
OLTP 5 Week 24-3.32 ± 2.294-1.45 ± 2.716
OLTP 5 Week 52-1.67 ± 3.066-3.30 ± 2.821
SecondaryAbsolute Change From Baseline in HbA1c for Participants With Baseline HbA1c ≥7%
Time frame:
Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 12, 24, 52
Reported as:
Mean · Percentage of HbA1c
Absolute Change From Baseline in HbA1c for Participants With Baseline HbA1c ≥7%
Percentage of HbA1cTreatment Sequence ATreatment Sequence B
Week 16-0.60 ± 2.200-0.36 ± 1.820
Week 24-2.34 ± 1.897-0.77 ± 2.145
Week 36-2.56 ± 1.985-0.74 ± 2.305
Week 52-2.69 ± 2.120-1.65 ± 2.554
OLTP 5 Week 12-3.57 ± 1.957-1.53 ± 2.472
OLTP 5 Week 24-3.32 ± 2.294-1.45 ± 2.716
OLTP 5 Week 52-1.67 ± 3.066-3.30 ± 2.821
SecondaryAbsolute Change From Baseline in Weighted Mean Glucose (WMG)
Time frame:
Baseline, Weeks 16 and 24
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Weighted Mean Glucose (WMG)
mg/dLTreatment Sequence ATreatment Sequence B
Week 16-10.626 ± 28.6416-7.579 ± 96.4257
Week 24-73.634 ± 67.7436-49.107 ± 85.0349
SecondaryAbsolute Change From Baseline in WMG for Participants With Baseline Fasting HbA1c ≥7%
Time frame:
Baseline, Weeks 16 and 24
Reported as:
Mean · mg/dL
Absolute Change From Baseline in WMG for Participants With Baseline Fasting HbA1c ≥7%
mg/dLTreatment Sequence ATreatment Sequence B
Week 16-10.626 ± 28.6416-4.510 ± 111.0606
Week 24-73.634 ± 67.7436-53.797 ± 92.1541
SecondaryChange From Baseline in Glucose Area Under the Concentration-time Curve (AUC0-4) During a Mixed Meal Tolerance Test (MMTT)
Time frame:
Baseline, Weeks 8, 16, 24
Reported as:
Mean · mg/dL*minutes
Change From Baseline in Glucose Area Under the Concentration-time Curve (AUC0-4) During a Mixed Meal Tolerance Test (MMTT)
mg/dL*minutesTreatment Sequence ATreatment Sequence B
Week 8829.3 ± 12465.831479.3 ± 6075.13
Week 16-5300.7 ± 12605.153734.1 ± 22343.37
Week 24-18000.6 ± 14760.99-5777.7 ± 14328.54
SecondaryChange From Baseline in Glucose AUC0-4 During a MMTT for Participants With Baseline HbA1c ≥7%
Time frame:
Baseline, Weeks 8, 16, 24
Reported as:
Mean · mg/dL*minutes
Change From Baseline in Glucose AUC0-4 During a MMTT for Participants With Baseline HbA1c ≥7%
mg/dL*minutesTreatment Sequence ATreatment Sequence B
Week 8829.3 ± 12465.833098.2 ± 5145.73
Week 16-5300.7 ± 12605.155976.4 ± 25141.92
Week 24-18000.6 ± 14760.99-5828.2 ± 15695.44
SecondaryChange From Baseline in Glucose Infusion Rate Per Kilogram (kg) Body Mass During Hyperinsulinemia-euglycemic Clamp
Time frame:
Baseline, Weeks 8 and 52
Reported as:
Mean · mg/kg/min
Change From Baseline in Glucose Infusion Rate Per Kilogram (kg) Body Mass During Hyperinsulinemia-euglycemic Clamp
mg/kg/minTreatment Sequence ATreatment Sequence B
Week 80.030 ± 0.42244.789 ± 7.3736
Week 526.256 ± NA4.776 ± 3.0924
SecondaryChange From Baseline in Glucose Infusion Rate Per kg Body Mass During Hyperinsulinemia-euglycemic Clamp for Participants With Baseline HbA1c ≥7%
Time frame:
Baseline, Weeks 8 and 52
Reported as:
Mean · mg/kg/min
Change From Baseline in Glucose Infusion Rate Per kg Body Mass During Hyperinsulinemia-euglycemic Clamp for Participants With Baseline HbA1c ≥7%
mg/kg/minTreatment Sequence ATreatment Sequence B
Week 80.030 ± 0.42240.572 ± 1.4186
Week 526.256 ± NA3.740 ± 2.8121
SecondaryChange From Baseline in Glucose Clearance Rate (kITT) During Insulin-tolerance Test (ITT)
Time frame:
Baseline, Weeks 8 and 52
Reported as:
Mean · %mg/dL/min
Change From Baseline in Glucose Clearance Rate (kITT) During Insulin-tolerance Test (ITT)
%mg/dL/minTreatment Sequence ATreatment Sequence B
Week 80.021 ± NA2.230 ± 2.4771
Week 522.311 ± 0.17120.632 ± 0.2064
SecondaryChange From Baseline in Glucose kITT During ITT for Participants With Baseline HbA1c ≥7%
Time frame:
Baseline, Weeks 8 and 52
Reported as:
Mean · %mg/dL/min
Change From Baseline in Glucose kITT During ITT for Participants With Baseline HbA1c ≥7%
%mg/dL/minTreatment Sequence ATreatment Sequence B
Week 80.021 ± NA2.230 ± 2.4771
Week 522.311 ± 0.17120.632 ± 0.2064
SecondaryNumber of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Time frame:
From first dose of DBTP study treatment through last dose of OLTP 5 study treatment plus 16 weeks (approximately 120 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
ParticipantsTreatment Sequence ATreatment Sequence B
DBTP 1-378
OLTP 487
OLTP 516
SecondaryConcentrations of Total REGN4461 in Serum Over Time
Time frame:
Weeks 0 (post-dose), 8, 16 (post-dose), 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Reported as:
Mean · mg/L
Concentrations of Total REGN4461 in Serum Over Time
mg/LTreatment Sequence ATreatment Sequence B
Week 0 (post-dose)0 ± 049.2 ± 13.8
Week 845.8 ± 6.822.51 ± 3.11
Week 16 (post-dose)2.34 ± 3.4450.6 ± 38.7
Week 3654.3 ± 36.467.7 ± 44.2
Week 5260.1 ± 45.168.8 ± 41.2
OLTP 5 Week 4167 ± 72.2167 ± 60.6
OLTP5 Week 12185 ± 67.2194 ± 80.6
OLTP5 Week 36156 ± 77.0355 ± 166
OLTP5 Week 52196 ± 106378 ± 224
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) to REGN4461
Time frame:
Approximately Week 128
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) to REGN4461
ParticipantsTreatment Sequence ATreatment Sequence B
Number of Participants With Anti-drug Antibodies (ADA) to REGN446100
PrimaryAbsolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8

Absolute change from baseline in HbA1c for subgroup of participants with baseline HbA1c ≥7% reported

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · millimoles per mole (mmol/mol)
Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8
millimoles per mole (mmol/mol)Treatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW
Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8-0.1 ± 0.60.2 ± 0.7
Statistical analysis
  • Treatment Sequence A, DBTP 1: Placebo SC QW vs Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW · Least squares (ls) mean difference: 0.2 · 95% CI -1.9 to 2.3Confidence interval (CI) based on treatment group difference (R4461 Low dose vs. placebo) of the LS means using mixed-effect model with repeated measures (MMRM) model
PrimaryAbsolute Change From Baseline in Fasting Glucose at Week 8

Absolute change from baseline in fasting glucose for subgroup of participants with baseline HbA1c ≥7% reported

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Absolute Change From Baseline in Fasting Glucose at Week 8
milligrams per deciliter (mg/dL)Treatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW
Absolute Change From Baseline in Fasting Glucose at Week 815.5 ± 18.653.6 ± 19.9
Statistical analysis
  • Treatment Sequence A, DBTP 1: Placebo SC QW vs Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW · Ls mean difference: 38.1 · 95% CI -21.3 to 97.5Confidence interval (CI) based on treatment group difference (R4461 Low dose vs. placebo) of the LS means using mixed-effect model with repeated measures (MMRM) model
PrimaryAbsolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8

Absolute change from baseline in WMG for subgroup of participants with baseline HbA1c ≥7% reported

Time frame:
Baseline, Week 8
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8
mg/dLTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW
Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8-3.7 ± 19.9-3.7 ± 23.4
Statistical analysis
  • Treatment Sequence A, DBTP 1: Placebo SC QW vs Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW · Adjusted mean difference: 0.0 · 95% CI -56.9 to 56.9Combined estimate for adjusted mean difference (SE) vs Placebo obtained by combining adjusted means and SE from ANCOVA model analyses of the different imputed data sets.
PrimaryPercent Change From Baseline in Fasting Triglycerides (TG) at Week 8

Percent change from baseline in participants with elevated baseline fasting TG (fasting TG ≥250 mg/dL) reported

Time frame:
Baseline, Week 8
Reported as:
Mean · percentage of change
Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8
percentage of changeTreatment Sequence A, DBTP 1: Placebo SC QWTreatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW
Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8-6.0 ± 29.811.8 ± 29.8
Statistical analysis
  • Treatment Sequence A, DBTP 1: Placebo SC QW vs Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW · Adjusted mean difference: 17.8 · 95% CI -67.6 to 103.2Combined estimate for adjusted mean difference (SE) vs Placebo obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets.

Adverse events

Collected over From first dose of study drug through end of study (approximately 128 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Sequence A: DBTP 10/8 (0%)1/8 (12.5%)6/8 (75%)
Treatment Sequence B: DBTP 10/8 (0%)0/8 (0%)7/8 (87.5%)
Treatment Sequence A: DBTP 20/8 (0%)0/8 (0%)6/8 (75%)
Treatment Sequence B: DBTP 20/8 (0%)0/8 (0%)7/8 (87.5%)
Treatment Sequence A: DBTP 30/8 (0%)1/8 (12.5%)5/8 (62.5%)
Treatment Sequence B: DBTP 30/8 (0%)1/8 (12.5%)6/8 (75%)
Treatment Sequence A: OLTP 40/8 (0%)1/8 (12.5%)8/8 (100%)
Treatment Sequence B: OLTP 40/8 (0%)3/8 (37.5%)7/8 (87.5%)
Treatment Sequence A: OLTP 50/6 (0%)1/6 (16.7%)5/6 (83.3%)
Treatment Sequence B: OLTP 50/4 (0%)1/4 (25%)3/4 (75%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTreatment Sequence A: DBTP 1Treatment Sequence B: DBTP 1Treatment Sequence A: DBTP 2Treatment Sequence B: DBTP 2Treatment Sequence A: DBTP 3Treatment Sequence B: DBTP 3Treatment Sequence A: OLTP 4Treatment Sequence B: OLTP 4Treatment Sequence A: OLTP 5Treatment Sequence B: OLTP 5
Cardiac failureCardiac disorders0/80/80/80/80/80/80/80/80/61/4
COVID-19Infections and infestations0/80/80/80/80/80/80/80/81/60/4
HyperglycaemiaMetabolism and nutrition disorders0/80/80/80/80/80/80/80/81/60/4
Mesangioproliferative glomerulonephritisRenal and urinary disorders0/80/80/80/80/80/80/80/81/60/4
Pancreatitis necrotisingGastrointestinal disorders1/80/80/80/80/80/80/80/80/60/4
Autoimmune thyroiditisEndocrine disorders0/80/80/80/80/80/81/80/80/60/4
Abdominal pain upperGastrointestinal disorders0/80/80/80/81/80/80/80/80/60/4
Stoma site infectionInfections and infestations0/80/80/80/80/80/80/81/80/60/4
Anastomotic ulcerInjury, poisoning and procedural complications0/80/80/80/80/81/80/80/80/60/4
Acute kidney injuryRenal and urinary disorders0/80/80/80/80/80/80/81/80/60/4
Most frequent other events
Showing 10 of 179
Most frequent other events
EventTreatment Sequence A: DBTP 1Treatment Sequence B: DBTP 1Treatment Sequence A: DBTP 2Treatment Sequence B: DBTP 2Treatment Sequence A: DBTP 3Treatment Sequence B: DBTP 3Treatment Sequence A: OLTP 4Treatment Sequence B: OLTP 4Treatment Sequence A: OLTP 5Treatment Sequence B: OLTP 5
HypoglycaemiaMetabolism and nutrition disorders0/82/80/83/81/81/83/84/80/61/4
NauseaGastrointestinal disorders0/81/80/80/81/80/80/83/82/60/4
VomitingGastrointestinal disorders0/80/80/80/80/81/80/83/81/60/4
Back painMusculoskeletal and connective tissue disorders1/80/80/80/80/80/80/81/82/61/4
HypertensionVascular disorders0/80/81/80/80/80/80/80/82/60/4
COVID-19Infections and infestations1/80/80/80/80/80/82/81/80/60/4
Urinary tract infectionInfections and infestations0/81/80/80/80/80/80/82/80/60/4
HypokalaemiaMetabolism and nutrition disorders1/82/80/80/80/80/81/82/80/60/4
HeadacheNervous system disorders1/80/80/80/81/80/81/82/81/61/4
ThrombocytopeniaBlood and lymphatic system disorders0/82/80/80/81/81/80/80/80/60/4

Baseline characteristics

Double-blind safety analysis set (SAF) (all randomized participants who received any double-blind study drug. Participants analyzed according to the treatment received).

Age, Continuous
Age, Continuous(Years)Treatment Sequence A, DBTP 1-3Treatment Sequence B, DBTP 1 -3Total
Mean19.8 ± 4.9530.3 ± 16.0625.0 ± 12.70
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence A, DBTP 1-3Treatment Sequence B, DBTP 1 -3Total
Female6814
Male202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence A, DBTP 1-3Treatment Sequence B, DBTP 1 -3Total
Hispanic or Latino314
Not Hispanic or Latino5712
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence A, DBTP 1-3Treatment Sequence B, DBTP 1 -3Total
American Indian or Alaska Native202
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American022
White6511
More than one race000
Unknown or Not Reported000
08

Study locations

8 sites
  • Regeneron Research Site
    Bethesda, Maryland 20892, United States
  • Regeneron Research Site
    Ann Arbor, Michigan 48105, United States
  • Regeneron Research Site
    Dallas, Texas 75390, United States
  • Regeneron Research Site
    Piura, 2665, Peru
  • Regeneron Research Site
    Moscow, 117036, Russia
  • Regeneron Research Site
    Ankara, 06230, Turkey (Türkiye)
  • Regeneron Research Site
    Diyarbakır, 21808, Turkey (Türkiye)
  • Regeneron Research Site
    Izmir, 35100, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual patient data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jan 2022, 23 months.

Results were first posted in Feb 2025, 3 years 1 month after primary completion. A results delay was requested in Jan 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2019
First posted
Nov 12, 2019
StartActual
Jan 7, 2020
Primary completionActual
Jan 5, 2022
CompletionActual
Sep 24, 2024
Results delay requested
Jan 4, 2023
Results first posted
Feb 25, 2025
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04159415
Responsible party
Sponsor
First posted
Nov 12, 2019
Start date
Jan 7, 2020
Primary completion
Jan 5, 2022
Completion
Sep 24, 2024
Results posted
Feb 25, 2025
Last update
Jun 15, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mibavademab

Start the discussion